Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Approval Strengthens Top Spot For AstraZeneca's Tagrisso

Gets EU Nod for Early-Stage NSCLC

Executive Summary

Competition may be on the horizon but Tagrisso's position as standard of care for EGFR-mutated NSCLC looks solid, not least after a thumbs-up in the EU for the adjuvant treatment of adults with early-stage disease.

You may also be interested in...



AstraZeneca Focuses On COVID-19 Antibody Approach After Year Of Vaccine Headwinds

During its fourth quarter earnings call, the UK-based major expressed hopes that its prophylactic antibody approach would fare better after its COVID-19 jab faced several obstacles in developed markets last year.

J&J’s Rybrevant May Find Limited Uptake Outside Academic Centers

The lung cancer drug’s side effects may deter some community oncologists, while a potentially safer drug earlier in development could prove more attractive.

EQRx's Aumolertinib May Be A Serious Competitive Contender For Tagrisso

The price of aumolertinib will be "radically lower" than what has become commonplace for cancer medicines, president Melanie Nallicheri told Scrip.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC144439

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel